Here's what startups took home wins at CERAWeek. Photo by Natalie Harms/InnovationMap

Over 200 startups participated in CERAWeek this year, and 18 of those companies pitched at a Greater Houston Partnership event.

The Houston Energy Transition Initiative, an initiative to promote Houston's work within the energy transition, hosted its second annual HETI Energy Ventures Competition at CERAWeek Innovation Agora. The competition was divided into four categories. The first batch of startups consisted of five companies from the Texas Entrepreneurship Exchange for Energy, or TEX-E, a collaboration with Greentown Labs, MIT’s Martin Trust Center for Entrepreneurship, and universities across Texas.

The winning startups shared $50,000 of prizes, sponsored by TEX-E. Houston-based Helix Earth Technologies — which has developed high-speed, high-efficiency filter systems derived from technology originating at NASA — won both the first place prize and fan favorite for the category. Helix's co-founders, Rawand Rasheed and Brad Husick from Rice University, walked away with $25,000 in prizes

Founded by Bryon Praslicka, Daniel Zamarron, and Craig Newman from Texas A&M University, Flux Works LLC, and its magnetic gear technology, took second place and $15,000 home. Tierra Climate, a two-sided marketplace for carbon offsets and other sustainability efforts founded by Emma Konet and Jacob Mansfield from Rice University, won third place and $10,000.

Helix Earth Technologies walked away with the top prize of the TEX-E category. Photo via greentownlabs.com

The next sets of startup pitches we broken down by funding stages — pre-seed and seed, series A, and series B and beyond.

Red Shift Energy, uses plasma energy to produce hydrogen from hydrogen sulfide, won fan favorite in the pre-seed and seed category sponsored by HX Venture Fund. A member of Halliburton Labs, the company also was recognized as Chevron favorite.

Per the judging panel, CanaGas won the title of most promising in the pre-seed and seed category sponsored by Alchemy Industrial. The Canadian company liquifies natural gas without costly cryogenics or stripping of the gas.

Houston-based Criterion Energy Partners won both the most-promising series A company category sponsored by SLB, but also the fan favorite series A category sponsored by Guerrella LLC. A geothermal energy tech company, Criterion was also a member of Rice's inaugural Clean Energy Accelerator cohort.

OptiSeis Solutions also won in both categories for the series B track. The company, a geophysical acquisition design and software company, won the title of most promising in the series B category sponsored by Pana LCE Investments and the series B fan favorite category sponsored by Halliburton Labs.

Lastly, the competition named the Most Impactful DEI, a category sponsored by Pana LCE Investments. Austin-based Gazelle Ecosystems, a social innovation startup with eco-solutions for corporations, won that category.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Nominations are now open for the 2025 Houston Innovation Awards

Calling All Innovators

Calling all Houston innovators: The Houston Innovation Awards return this fall to celebrate the best and brightest in the Houston innovation ecosystem right now.

Presented by InnovationMap, the fifth annual Houston Innovation Awards will take place November 5 at TMC Helix Park.

The awards program will honor the top startups and innovators in Houston across 10 categories, and we're asking you to nominate the most deserving Houston innovators and innovative companies today.

This year's categories are:

  • Minority-founded Business, honoring an innovative startup founded or co-founded by BIPOC or LGBTQ+ representation.
  • Female-founded Business, honoring an innovative startup founded or co-founded by a woman.
  • Energy Transition Business, honoring an innovative startup providing a solution within renewables, climatetech, clean energy, alternative materials, circular economy, and beyond.
  • Health Tech Business, honoring an innovative startup within the health and medical technology sectors.
  • Deep Tech Business, honoring an innovative startup providing technology solutions based on substantial scientific or engineering challenges, including those in the AI, robotics, and space sectors.
  • Startup of the Year (People's Choice), honoring a startup celebrating a recent milestone or success. The winner will be selected by the community via an interactive voting experience.
  • Scaleup of the Year, honoring an innovative later-stage startup that's recently reached a significant milestone in company growth.
  • Incubator/Accelerator of the Year, honoring a local incubator or accelerator that is championing and fueling the growth of Houston startups.
  • Mentor of the Year, honoring an individual who dedicates their time and expertise to guide and support budding entrepreneurs.
  • Trailblazer, honoring an innovator who's made a lasting impact on the Houston innovation community.

Nominations may be made on behalf of yourself, your organization, and other leaders in the local innovation scene. The nomination period closes on August 31, so don't delay — nominate today at this link, or fill out the embedded form below.

Our panel of esteemed judges will review the nominations, and determine the finalists and winners. Finalists will be unveiled on September 30, and the 2025 Houston Innovation Awards winners will be announced live at our event on November 5.

Tickets will go on sale this fall. Stay tuned for that announcement, as well as more fanfare leading up to the 2025 Houston Innovation Awards.

Nominate now:

Interested in Innovation Awards sponsorship opportunities? Please contact sales@innovationmap.com.

MD Anderson launches $10M collaboration to advance personalized cancer treatment tech

fighting cancer

The University of Texas MD Anderson Cancer Center and Japan’s TOPPAN Holdings Inc. have announced a strategic collaboration to co-develop TOPPAN Holdings’ 3D cell culture, or organoid, technology known as invivoid.

The technology will be used as a tool for personalized cancer treatments and drug screening efforts, according to a release from MD Anderson. TOPPAN has committed $10 million over five years to advance the joint research activities.

“The strategic alliance with MD Anderson paves a promising path toward personalized cancer medicine," Hiroshi Asada, head of the Business Innovation Center at TOPPAN Holdings, said in a news release.

Invivoid is capable of establishing organoid models directly from patient biopsies or other tissues in a way that is faster and more efficient. Researchers may be able to test a variety of potential treatments in the laboratory to understand which approach may work best for the patient, if validated clinically.

“Organoids allow us to model the three-dimensional complexity of human cancers in the lab, thus allowing us to engineer a powerful translational engine—one that could not only predict how patients will respond to therapy before treatment begins but also could help to reimagine how we discover and validate next-generation therapies," Dr. Donna Hansel, division head of pathology and laboratory medicine at MD Anderson, added in the news release. “Through this collaboration, we hope to make meaningful progress in modeling cancer biology for therapeutic innovation.”

The collaboration will build upon preclinical research previously conducted by MD Anderson and TOPPAN. The organizations will work collaboratively to obtain College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certifications for the technology, which demonstrate a commitment to high-quality patient care. Once the certifications are obtained, they plan to conduct observational clinical studies and then prospective clinical studies.

“We believe our proprietary invivoid 3D cell culture technology, by enabling the rapid establishment of organoid models directly from patient biopsies, has strong potential to help identify more effective treatment options and reduce the likelihood of unnecessary therapies,” Asada added in the release. “Through collaboration on CAP/CLIA certification and clinical validation, we aim to bring this innovation closer to real-world patient care and contribute meaningfully to the advancement of cancer medicine."